<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01126255</url>
  </required_header>
  <id_info>
    <org_study_id>213/08</org_study_id>
    <nct_id>NCT01126255</nct_id>
  </id_info>
  <brief_title>Progesterone vs Clobetasol Propionate in Vulvar Lichen Sclerosus</brief_title>
  <official_title>Efficacy of a Topic Therapy With Progesterone Compared to the Conventional Therapy With Clobetasol Propionate in Patients With Vulvar Lichen Sclerosus. A Double Blind, Randomized Phase II Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized trial comparing progesterone with conventional clobetasol propionate in&#xD;
      patients with vulvar lichen sclerosus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background&#xD;
&#xD;
      A total of 62 female patients with first diagnosis of lichen sclerosus will be treated daily&#xD;
      with either topical progesterone 8% or clobetasol propionate 0.05% for 12 weeks. Response to&#xD;
      the treatment will be evaluated by macroscopic description of the dermatologic phenotype by&#xD;
      using a specific lichen sclerosus score and photography-documentation. The symptoms and&#xD;
      quality of life of the patients will be evaluated by standardized questionnaires.&#xD;
      Additionally, tissue samples will be taken before and again after 12 weeks of treatment to&#xD;
      evaluate the response status.&#xD;
&#xD;
      Objective&#xD;
&#xD;
      The purpose of this study is to compare progesterone with conventional clobetasol propionate&#xD;
      in a superiority trial.&#xD;
&#xD;
      Methods&#xD;
&#xD;
      Prospective, randomized, controlled, superiority phase II pilot trial. Patients will be&#xD;
      randomized 1:1 to either progesterone or clobetasol propionate, with patients, physicians,&#xD;
      assessors and analysts being blinded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment problems&#xD;
  </why_stopped>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Score of the characteristics of Lichen sclerosus based on vulvar efflorescences</measure>
    <time_frame>at 12 weeks</time_frame>
    <description>The severity of the Lichen sclerosus will be assessed by a metric score, which is based on 6 items (abrasion, hyperkeratosis, rhagades, synechia, sclerosis, atrophy of labia/clitoris) consisting of three levels (0=no signs, 1=few signs, 2=pronounced signs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient-reported symptoms</measure>
    <time_frame>at baseline</time_frame>
    <description>The patient will report the following symptoms on a scale from 0 to 10 pruritus, burning or pain, sore.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>at baseline</time_frame>
    <description>The patient will report quality of life on the SF12 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>at baseline</time_frame>
    <description>The tolerability of the topical treatment will be assessed by all adverse events occuring at the site of application.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported symptoms</measure>
    <time_frame>at 6 weeks</time_frame>
    <description>The patient will report the following symptoms on a scale from 0 to 10: pruritus, burning or pain, sore.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported symptoms</measure>
    <time_frame>at 12 weeks</time_frame>
    <description>The patient will report the following symptoms on a scale from 0 to 10: pruritus, burning or pain, sore.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported symptoms</measure>
    <time_frame>at 18 weeks</time_frame>
    <description>The patient will report the following symptoms on a scale from 0 to 10 pruritus, burning or pain, sore.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported symptoms</measure>
    <time_frame>at 24 weeks</time_frame>
    <description>The patient will report the following symptoms on a scale from 0 to 10 pruritus, burning or pain, sore.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>at 12 weeks</time_frame>
    <description>The patient will report quality of life on the SF12 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>at 24 weeks</time_frame>
    <description>The patient will report quality of life on the SF12 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>at 6 weeks</time_frame>
    <description>The tolerability of the topical treatment will be assessed by all adverse events occuring at the site of application.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>at 12 weeks</time_frame>
    <description>The tolerability of the topical treatment will be assessed by all adverse events occuring at the site of application.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Vulvar Lichen Sclerosus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clobetasol propionate 0.05%, topical application, once daily about 2 g, during 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Progesterone 8%, topical application, once daily about 2 g, during 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clobetasol propionate 0.05%</intervention_name>
    <description>Topical application, once daily about 2 g, during 12 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone 8%</intervention_name>
    <description>Topical application, once daily about 2 g, during 12 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Consent to biopsy at start and end of therapy&#xD;
&#xD;
          -  Suspicion of Lichen sclerosus&#xD;
&#xD;
          -  Pre-menopausal&#xD;
&#xD;
          -  Age â‰¥18 years&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Prior surgery at the vulva, with exception of episiotomy&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Signs of infection with human papilloma virus at the vulva&#xD;
&#xD;
          -  Vulvar intraepithelial neoplasia (VIN)&#xD;
&#xD;
          -  Known generalised autoimmune disease&#xD;
&#xD;
          -  Lichen sclerosus since childhood&#xD;
&#xD;
          -  Prior therapy with topic clobetasol propionate or other immunosuppressives (tacrolimus&#xD;
             or pimecrolimus) at the vulva&#xD;
&#xD;
          -  Atopic diathesis and/or contact allergy&#xD;
&#xD;
          -  Systemic immunosuppressive therapy&#xD;
&#xD;
          -  Genital infection within the last four weeks (eg., condyloma acuminata, candidiasis)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Guenthert, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Dep. of Obstetrics and Gynecology, Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>May 7, 2010</study_first_submitted>
  <study_first_submitted_qc>May 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2010</study_first_posted>
  <last_update_submitted>October 7, 2014</last_update_submitted>
  <last_update_submitted_qc>October 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2014</last_update_posted>
  <responsible_party>
    <name_title>PD Dr. med. A. Guenthert</name_title>
    <organization>Dep. of Obstetrics and Gynecology, Bern University Hospital</organization>
  </responsible_party>
  <keyword>vulvar lichen sclerosus</keyword>
  <keyword>progesterone</keyword>
  <keyword>clobetasol</keyword>
  <keyword>randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vulvar Lichen Sclerosus</mesh_term>
    <mesh_term>Lichen Sclerosus et Atrophicus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clobetasol</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

